TG2 is up-regulated during cardiac hypertrophy and heart failure in animal models, whereas its activity (GTP binding and GTPase) has been found to be down-regulated in patients with ischemic and dilated cardiomyopathies (Sane et al. 2007). Here, TGM2 is linked to dilated cardiomyopathy.